News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,926 Results
Type
Article (14277)
Company Profile (281)
Press Release (254368)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79544)
Career Advice (153)
Deals (13231)
Drug Delivery (35)
Drug Development (50469)
Employer Resources (31)
FDA (5728)
Job Trends (5139)
News (144460)
Policy (10034)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21681)
ALS (69)
Alzheimer's disease (851)
Antibody-drug conjugate (ADC) (108)
Approvals (5754)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1524)
Cardiovascular disease (121)
Career advice (134)
Career pathing (2)
CAR-T (123)
Cell therapy (342)
Cervical cancer (9)
Clinical research (41177)
Collaboration (560)
Compensation (281)
Complete response letters (13)
COVID-19 (1034)
CRISPR (44)
C-suite (172)
Cystic fibrosis (78)
Data (1619)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1303)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (92)
Earnings (30132)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48800)
Executive appointments (475)
FDA (6501)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (516)
Gene editing (102)
Generative AI (10)
Gene therapy (265)
GLP-1 (372)
Government (1084)
Grass and pollen (2)
Guidances (70)
Healthcare (6595)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (20)
Infectious disease (1101)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7282)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1386)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (63)
Medical device (2603)
Medtech (2604)
Mergers & acquisitions (6290)
Metabolic disorders (407)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (73)
Neuropsychiatric disorders (25)
Neuroscience (1278)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (22)
Obesity (197)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (124)
Partnered (8)
Patents (137)
Patient recruitment (83)
Peanut (35)
People (25684)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14548)
Phase II (19160)
Phase III (12099)
Pipeline (947)
Policy (49)
Postmarket research (852)
Preclinical (6161)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (299)
Real estate (1419)
Recruiting (12)
Regulatory (8678)
Reports (17)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (64)
Series A (100)
Series B (70)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (217)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (71)
Last 7 days (615)
Last 30 days (1882)
Last 365 days (19331)
2025 (7105)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17354)
Australia (2944)
California (4077)
Canada (1177)
China (378)
Colorado (153)
Connecticut (156)
Delaware (110)
Europe (37349)
Florida (498)
Georgia (124)
Idaho (16)
Illinois (240)
India (10)
Indiana (94)
Iowa (2)
Japan (80)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (493)
Massachusetts (3251)
Michigan (74)
Minnesota (152)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1012)
New Mexico (12)
New York (1091)
North Carolina (572)
North Dakota (5)
Northern California (1821)
Ohio (115)
Oklahoma (9)
Oregon (21)
Pennsylvania (771)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1563)
Tennessee (25)
Texas (472)
United States (13926)
Utah (56)
Virginia (84)
Washington D.C. (31)
Washington State (362)
Wisconsin (17)
268,926 Results for "oncternal therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Oncternal to Lay Off 37% of Employees, Including CMO
Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales or an M&A.
September 13, 2024
·
1 min read
·
Angela Gabriel
Deals
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2024
Oncternal Therapeutics, Inc. today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management.
May 1, 2024
·
3 min read
Business
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported first quarter 2024 financial results.
May 9, 2024
·
8 min read
Business
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
Oncternal Therapeutics, Inc. announced that it will report first quarter 2024 financial results after the U.S. financial markets close on Thursday, May 9, 2024.
May 2, 2024
·
2 min read
Biotech Beach
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
February 6, 2024
·
3 min read
Press Releases
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
July 12, 2024
·
3 min read
Business
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - February 1, 2024
Oncternal Therapeutics, Inc. today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science.
February 1, 2024
·
3 min read
Press Releases
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
September 12, 2024
·
7 min read
Business
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics, Inc. announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024.
February 29, 2024
·
2 min read
Business
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.
March 7, 2024
·
9 min read
1 of 26,893
Next
